| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion |
ANCHOR, NCT06422689: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care |
|
|
| Recruiting | 4 | 2000 | US | Albuterol and budesonide inhalation aerosol, PT027 | AstraZeneca, Premier HealthCare Solutions Inc. | Asthma | 04/26 | 04/26 | | |
NCT06158893: Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy |
|
|
| Not yet recruiting | 4 | 87 | NA | Salbutamol, Budesonide, Saline | Assiut University | Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy | 08/25 | 10/25 | | |
DARWIN, NCT06563102: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma |
|
|
| Recruiting | 4 | 100 | US | Albuterol/Budesonide, AIRSUPRA, BDA MDI HFA, Albuterol, AS MDI | AstraZeneca, Fortrea | Mild Asthma | 11/25 | 11/25 | | |
2018-003674-27: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI). |
|
|
| Not yet recruiting | 3 | 1000 | Europe, RoW | Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), Budesonide Pressurized Inhalation Suspension (BD MDI), PT027, PT007, PT008, Pressurised inhalation, suspension | Bond Avillion 2 Development LP, Bond Avillion 2 Development LP | Symptomatic Asthma, Symptomatic Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003673-10: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007 in asthma patients 4 years of age or older (MANDALA). |
|
|
| Not yet recruiting | 3 | 3100 | Europe, RoW | Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), PT027, PT007, Pressurised inhalation, suspension, Ventolin Evohaler® 100 micrograms | Bond Avillion 2 Development LP, Bond Avillion 2 Development LP | Moderate to severe asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
BREATH, NCT06245551: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma |
|
|
| Completed | 3 | 64 | RoW | Budesonide/albuterol metered-dose inhaler 160/180 μg, PT027 (BDA MDI) 160/180 μg, Placebo metered-dose inhaler, Placebo MDI | AstraZeneca | Asthma, Exercise-Induced | 06/24 | 06/24 | | |
NCT05555290: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction |
|
|
| Recruiting | 3 | 105 | US | PT027, PT007 | AstraZeneca | Asthma | 12/24 | 12/24 | | |
NCT05505734: A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
|
|
| Completed | 3 | 2517 | US | BDA MDI, AS MDI | Bond Avillion 2 Development LP, Parexel | Asthma | 08/24 | 08/24 | | |
ACADIA, NCT06307665: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 440 | US, RoW | BDA MDI, PT027, AS MDI, PT007 | AstraZeneca, Parexel | Asthma | 10/27 | 10/27 | | |
| Not yet recruiting | 3 | 1038 | NA | Budesonide/formoterol, No other intervention names, standard of care, beclomethasone or budesonide & salbutamol or mentelukast | University of KwaZulu | Asthma | 05/25 | 05/26 | | |
BAIYUN, NCT06471257: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma |
|
|
| Recruiting | 3 | 790 | RoW | Budesonide/Albuterol metered dose inhaler, MDI, PT027, Albuterol sulfate metered dose inhaler, MDI, PT007 | AstraZeneca | Asthma | 09/26 | 09/26 | | |
NCT06502366: A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma |
|
|
| Recruiting | 3 | 398 | Europe, US, RoW | BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA | AstraZeneca | Asthma | 02/26 | 02/26 | | |
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
|
|
| Recruiting | 3 | 300 | Europe, Canada, US, RoW | Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA | AstraZeneca, Fortrea | Severe Asthma | 06/27 | 06/27 | | |
ChiCTR2400085445: A Randomized, Double-blind, Multicentre, Event-driven, Parallel group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared with PT007 Administered As Needed in Symptomatic Chinese Adults with Asthma (BAIYUN) |
|
|
| Not yet recruiting | 3 | 790 | | BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 μg) as needed; AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg) as needed | West China Hospital of Sichuan University; AstraZeneca Global R&D (China) Co.,LTD, Secondary sponsor:AstraZeneca Global R&D(China) Co.,LTD | Asthma | | | | |
NCT06139991: Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant. |
|
|
| Completed | 1 | 66 | US | Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA) | AstraZeneca | Heathy Participants | 05/24 | 05/24 | | |
PUTUO, NCT06514157: Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. |
|
|
| Completed | 1 | 14 | RoW | budesonide/albuterol sulfate metered dose inhaleor (BDA MDI) | AstraZeneca | Healthy Volunteer | 09/24 | 09/24 | | |
ChiCTR2200059926: Effects of combined use of salbutamol/budesonide in thoracic surgery on postoperative myocardial injury (MINS) – A prospective randomized clinical trial |
|
|
| Completed | N/A | 304 | | None ;Salbutamol/budesonide | Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, tutor provide | postoperative myocardial injury | | | | |
